kt 6149 has been researched along with carubicin in 1 studies
Studies (kt 6149) | Trials (kt 6149) | Recent Studies (post-2010) (kt 6149) | Studies (carubicin) | Trials (carubicin) | Recent Studies (post-2010) (carubicin) |
---|---|---|---|---|---|
39 | 3 | 0 | 340 | 40 | 1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bungo, M; Fujiwara, Y; Fukuda, M; Horichi, N; Minato, K; Nakagawa, K; Niimi, S; Ohe, Y; Saijo, N; Sasaki, Y | 1 |
1 other study(ies) available for kt 6149 and carubicin
Article | Year |
---|---|
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Menogaril; Mitomycins; Nogalamycin; Tumor Cells, Cultured | 1989 |